ロード中...
Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
Inhaled corticosteroids (ICSs) treatment combined with long-acting β(2)-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate...
保存先:
| 出版年: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5654780/ https://ncbi.nlm.nih.gov/pubmed/29089754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S143656 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|